Evidence map›Paper›PMID 42322509›Full record

ArticleEJNMMI research2026

Dual-time-point [

Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04300244 (Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04300244 phase2active not recruitingnot on this map

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)

TypeinterventionalSponsorÅslaug HellandRan2020 to 2027Enrolled118ConditionsCancer, Cancer, Lung, Cancer of Lung, MesotheliomaArmsUV1 vaccine + leukine, ipilimumab, nivolumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Solfrid ThunoldDepartment of Oncology, Oslo University Hospital, Oslo, Norway. solthu@ous-hf.no.ORCID http://orcid.org/0009-0004-9277-7796
Eivor HernesDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Lars Tore Gyland MikalsenDepartment of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Saima FarooqiDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Åsa Kristina ÖjlertDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Roslyn J FrancisDepartment of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
Anna K NowakMedical School, The University of Western Australia, Perth, WA, Australia.
Weronika Maria SzejniukClinical Cancer Research Center, Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
Søren Steen NielsenDepartment of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark.
Susana CedresVall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Marc Simo PerdigoDepartment of Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jens Benn SørensenDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Carin MeltzerDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Åslaug HellandDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Eirik MalinenDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Vilde Drageset HaakensenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background[

resultsAt week-5, RI tertiles showed stepwise separation for both OS (p = 0.038) and PFS (p = 0.031), with the lowest tertile associated with the most favourable outcomes. SUV

conclusionsWeek-5 [

trial registrationClinicalTrials.gov NCT04300244. Registered 2020-03-09. https://clinicaltrials.gov/study/NCT04300244.

Indexed as

[18F]FDGDual-time-point PETImmunotherapyPleural mesotheliomaRetention index

Identifiers

PMID42322509
PMCPMC13538317

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.